AKRO - Akero Therapeutics, Inc.

QQQ $ 475.90 $ 0.24 (0.05 %)

DIA $ 406.80 $ 0.86 (0.21 %)

SPY $ 555.29 $ 0.40 (0.07 %)

TLT $ 97.35 $ -0.59 (-0.6 %)

GLD $ 231.90 $ 5.08 (2.24 %)

Previous Close

$ 24.86

Open

Bid

$ 24.79 x 357

Ask

-- x --

Day's Range

-- - --

52 Week Range

$ 11.25 - $ 53.77

Volume

294,283

Average Volume

Market Cap

1.72B

Beta (5Y Monthly)

$ 0.27

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-09-2024	06-30-2024	10-Q
2	05-10-2024	03-31-2024	10-Q
3	02-29-2024	12-31-2023	10-K
4	11-13-2023	09-30-2023	10-Q
5	08-11-2023	06-30-2023	10-Q
6	05-15-2023	03-31-2023	10-Q
7	03-17-2023	12-31-2022	10-K
8	11-04-2022	09-30-2022	10-Q
9	08-04-2022	06-30-2022	10-Q
10	05-06-2022	03-31-2022	10-Q
11	02-25-2022	12-31-2021	10-K
12	11-12-2021	09-30-2021	10-Q
13	08-13-2021	06-30-2021	10-Q
14	05-13-2021	03-31-2021	10-Q
15	03-16-2021	12-31-2020	10-K
16	11-12-2020	09-30-2020	10-Q
17	08-12-2020	06-30-2020	10-Q
18	05-13-2020	03-31-2020	10-Q
19	03-16-2020	12-31-2019	10-K
20	11-12-2019	09-30-2019	10-Q
21	08-12-2019	06-30-2019	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

HC Wainwright & Co. Reiterates Buy on Aker...
08/12/2024 11:11:29

HC Wainwright & Co. analyst Ed Arce reiterates Akero Therapeutics (NASDAQ:AKRO) with a Buy and maintains $50 price target.

Akero Therapeutics Q2 EPS $(0.81) Beats $(...
08/09/2024 11:25:20

Akero Therapeutics (NASDAQ:AKRO) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(...

this-analyst-sees-potential-downside-in-eli-lilly-adjusts-model-for-acquired-iprd-charges

This Analyst Sees Potential Downside In El...
07/15/2024 17:13:12

Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on Eli Lilly with a price target of $885. Eli Lilly's...

Cantor Fitzgerald Reiterates Overweight on...
06/20/2024 17:18:41

Cantor Fitzgerald analyst Prakhar Agrawal reiterates Akero Therapeutics (NASDAQ:AKRO) with a Overweight.

Cantor Fitzgerald Reiterates Overweight on...
06/12/2024 16:09:56

Cantor Fitzgerald analyst Prakhar Agrawal reiterates Akero Therapeutics (NASDAQ:AKRO) with a Overweight.

Wolfe Research Initiates Coverage On Akero...
06/11/2024 18:43:03

Wolfe Research analyst Andy Chen initiates coverage on Akero Therapeutics (NASDAQ:AKRO) with a Outperform rating.

Akero Therapeutics Begins Phase 3 Study on...
06/11/2024 11:05:07

Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serio...

HC Wainwright & Co. Reiterates Buy on Aker...
06/11/2024 10:41:06

HC Wainwright & Co. analyst Ed Arce reiterates Akero Therapeutics (NASDAQ:AKRO) with a Buy and maintains $50 price target.

Reported Saturday, Akero Therapeutics Pres...
06/10/2024 07:44:56

A late-breaking oral presentation will feature 96-week data from HARMONY, a Phase 2b study evaluating the efficacy and safety o...

whats-going-on-with-fattly-liver-disease-focused-madrigal-pharmaceuticals-sagimet-biosciences-shares-on-wednesday

What's Going On With Fattly Liver Disease ...
06/05/2024 19:17:50

Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress ...

Evercore ISI Group Maintains Outperform on...
05/15/2024 13:17:45

Evercore ISI Group analyst Liisa Bayko maintains Akero Therapeutics (NASDAQ:AKRO) with a Outperform and lowers the price tar...

Canaccord Genuity Maintains Buy on Akero T...
05/13/2024 16:35:51

Canaccord Genuity analyst Edward Nash maintains Akero Therapeutics (NASDAQ:AKRO) with a Buy and lowers the price target from...

HC Wainwright & Co. Reiterates Buy on Aker...
05/13/2024 10:44:16

HC Wainwright & Co. analyst Ed Arce reiterates Akero Therapeutics (NASDAQ:AKRO) with a Buy and maintains $50 price target.

Akero Therapeutics Q1 EPS $(0.90) Beats $(...
05/10/2024 11:15:12

Akero Therapeutics (NASDAQ:AKRO) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate of $(...

B of A Securities Reinstates Neutral on Ak...
04/22/2024 10:21:38

B of A Securities analyst Alexandria Hammond reinstates Akero Therapeutics (NASDAQ:AKRO) with a Neutral and announces $30 pr...

Akero Therapeutics Publishes Phase 2b SYMM...
03/07/2024 21:02:33

As reported previously, the addition of EFX to GLP-1 receptor agonist therapy had a safety and tolerability profile comparable ...

Akero Therapeutics Prices Public Offering ...
03/06/2024 07:16:58

The comnay announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a public offeri...

Akero Therapeutics shares are trading lowe...
03/05/2024 17:25:29

UBS Maintains Buy on Akero Therapeutics, R...
03/05/2024 14:43:55

UBS analyst Eliana Merle maintains Akero Therapeutics (NASDAQ:AKRO) with a Buy and raises the price target from $39 to $42.

HC Wainwright & Co. Maintains Buy on Akero...
03/05/2024 11:46:20

HC Wainwright & Co. analyst Ed Arce maintains Akero Therapeutics (NASDAQ:AKRO) with a Buy and raises the price target fr...